RESUMO
In 12 X-ray and gastroenterology departments 1570 patients, clinically suspected to have a gastric pathology, have been examined by double contrast (surface) examination of the stomach followed by gastroscopy. Diagnostic accuracy was 93% in respect of endoscopic data, assumed correct by hypothesis. On the basis of a cost and benefit evaluation, made according to the well known criteria, a wider routine use of the double contrast technique is proposed.
Assuntos
Meios de Contraste/administração & dosagem , Gastroscopia/métodos , Estômago/diagnóstico por imagem , Adolescente , Adulto , Idoso , Ensaios Clínicos como Assunto , Erros de Diagnóstico , Reações Falso-Negativas , Reações Falso-Positivas , Humanos , Itália , Pessoa de Meia-Idade , Radiografia , Gastropatias/diagnóstico por imagemRESUMO
Eighty-four patients with endoscopically-proved active duodenal ulcer were admitted to a multicentre double-blind trial with either pirenzepine tablets (25 mg three times per day for 1 week followed by 25 mg two times per day for 3 weeks) or placebo. Seventy-nine patients completed the trial, 44 treated with pirenzepine and 35 with placebo. After 4 weeks, complete healing had been achieved in 52% of the pirenzepine-treated patients and in 34% of the placebo-treated ones. Symptomatic responses were signigicantly better in those receiving pirenzepine than in those receiving placebo. In addition, the supplementary antacid consumption was significantly lesser in the pirenzepine group than in the placebo group. No important side-effects were observed in the two groups.
Assuntos
Antiulcerosos/uso terapêutico , Benzodiazepinonas/uso terapêutico , Úlcera Duodenal/tratamento farmacológico , Piperazinas/uso terapêutico , Adulto , Fatores Etários , Ensaios Clínicos como Assunto , Método Duplo-Cego , Úlcera Duodenal/diagnóstico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pirenzepina , Placebos , Distribuição Aleatória , FumarRESUMO
Ninety-six patients with endoscopically proved active duodenal ulcers were admitted to a multicentre double-blind trial with either pirenzepine (100 mg/day, 25 mg in the morning and midday and 50 mg at bed time) or placebo for 4 weeks. Ninety-two patients (46 in each group) completed the trial. After 4 weeks, complete healing had been achieved in 70% of the pirenzepine-treated patients and in 32% of the placebo-treated ones (P less than 0.01). No important side-effects and no abnormal changes in blood values or urinalysis were observed during treatment. The difference in the ulcer healing rates observed in the two parts of this multicentre trial is briefly discussed.
Assuntos
Antiulcerosos/uso terapêutico , Benzodiazepinonas/uso terapêutico , Úlcera Duodenal/tratamento farmacológico , Piperazinas/uso terapêutico , Adulto , Ensaios Clínicos como Assunto , Método Duplo-Cego , Úlcera Duodenal/diagnóstico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pirenzepina , Placebos , Distribuição AleatóriaRESUMO
Pirenzepine (PRZ) 75 mg/day for 1 week followed by 50 mg/day for 3 weeks did not show a good activity in gastric ulcer healing in comparison to carbenoxolone (CB) (300 mg/day for 1 week followed by 200 mg/day for 3 weeks). The tolerability of PRZ seemed to be better than that of CB. The increase in the daily dose of PRZ to 100 mg/day for 4 weeks led to better results in the patients who have completed satisfactorily the treatment up to now. PRZ's tolerability was greater than CB's. The results of this study are preliminary to further trial.